AIM:To evaluate the efficacy of Bailemian Capsule(bulbus lilii,Radix et rhizome seu acanthopanacis senticosi caulis,Caulis polygoni multiflori,Flos albiziae,Concha margaritifera) in combination with buspirone in generalised anxiety disease. METHODS:Seventy-seven patients with generalized anxiety disease were randomly assigned to two groups:Bailemian Capsule in combination with buspirone in the treated group; buspirone alone in the control group. A period of six weeks was one treatment course in each group. The clinical effectiveness was evaluated according to HAMA reactions. RESULTS:HAMA score(P

OBJECTIVE:To observe the efficacy and adverse reaction of venlafaxine combined with Bailemian capsule for somatization disorder.METHODS:145 patients with somatization disorder were randomly assigned to receive venlafaxine alone (single group) or in combination with Bailemian capsule (combined group) for 8 weeks.Clinical global impression scale (CGI) and symptom check (SCL-90) were used to assess the efficacy and treatment emergent symptom scale (TESS) was used to assess the adverse reactions.RESULTS:After 8 weeks of treatment,CGI score showed the total effective rate were 88.14% for single group and 94.18% for combined group (P

Despite multimodel chemotherapy after successful surgical cytoreduction for ovarian cancer,disease recurrence continues to be problematic.Therefore,exploring new treatment strategy has already become urgent matter of the moment. Biological targeted therapies have been studied to overcome chemotherapy resistance.The most promising one at this time is bevacizumab.Results from phase Ⅱ and phase Ⅲ trials were excited.Deeper understanding of biologic pathway in ovarian cancer,and more biologic targets undergoing clinical trial will develop a new world for the treatment of ovarian cancer.

Objective To investigate the relationship between cytoreduction outcome and staging of ovarian cancer with preoperative blood cell count.Methods The data of 148 ovarian cancer patients from January 2007 to June 2012 were analyzed retrospectively.Clinicopathological and blood cell count data were collected,and benign ovarian tumor group (n =96) as controls.Results Compared to the control group,there were significant differences in the number of white blood cells,neutrophils,lymphocytes,monocytes,platelets,neutrophil to lymphocyte ratio,and platelets to lymphocyte ratio in patients with ovarian cancer (P ＜ 0.05).The same results were also observed in advanced groups and early groups.While between optimal cytoreduction and suboptimal cytoreduction,there were significant differences in platelets,monocytes,neutrophil to lymphocyte ratio,and platelets to lymphocyte ratio (P ＜ 0.05).Conclusions The cytoreduction outcome and pathological staging of ovarian cancer are closely related to the preoperative blood cell count.Blood cell count is important for the identification of benign and malignant ovarian tumors,cytoreduction outcome and the prediction of pathological staging,and may be of significance to the monitoring and prognosis of the disease.

OBJECTIVE:To observe the efficacy and safety of sertraline combined with Shumian capsule for depression of dyssomnia.METHODS:86 patients with depression were randomly assigned to receive sertraline alone(single group) or in combination with Shumian capsule(combined group) for 8 weeks.Clinical effectiveness was evaluated using HAMD and PSQI,and TESS was used to assess the adverse effects.RESULTS:After treatment for 8 weeks,the total effective rate was 88.2% for combined group and 85.7% for single group(P

Purpose:To evaluate the efficacy and toxicities of gemcitabine plus cisplatin for patients with relapsed ovarian cancer. Methods:Twenty-eight patients with recurrent ovarian carcinoma received gemcitabine (1000 mg/m~(2)) plus cisplatin (35 mg/m~(2)) on days 1 and 8 of each 21-day cycle. Of 28 patients, sixteen who relapsed within six months of previously platinum-based regimen were platinum-resistant and the other twelve were platinum-sensitive. Results:Of 28 patients, there were 5 (17.9%) complete and 12 (42.9%) partial responses, for an overall response rate of 60.7% (95%CI: 41.7%–79.6%). The median time to progression for objective responders was 5.5 months with a range of 2.5 to 20 months. Median overall survival for all 28 patients was 12.5 months. Among 16 platinum-resistant patients, a 56.3% response rate occurred. The median survival time was 10.5 months. Among 12 platinum-sensitive patients, a 66.7% response rate occurred. The median survival time was 14.5 months. There were leukopenia grade Ⅲ in 35.7%, grade Ⅳ in 17.9%; thrombocytopenia grade Ⅲ in 28.6 %, grade Ⅳ in 14.3% of patients. Conclusions:Cisplatin plus gemcitabine is active in patients with relapsed ovarian cancer. The adverse effects are tolerable. Hematologic toxicities are manageable with dose modifications.

Objective To compare the effect of ropivacaine mesylate with ropivacaine HC1 for patient-controlled epidural analgesia ( PCEA) after transabdominal hysterectomy. Methods Forty-four ASA 1 or D patients aged 18-65 yrs weighing 45-80 kg undergoing elective abdominal hysterectomy performed under epidural anesthesia with either 0.75% ropivacaine HO (control group, n = 22) or 0.894% ropivacaine mesylate (study group, n= 22) . An epidural catheter was placed at L2,3 and advanced 3 cm into the epidural space. After operation PCEA was performed with 0.2% ropivacaine HCl ( control group) or 0.237 % ropivacaine mesylate (study group) respectively. Postoperative pain was assessed using VAS (0-10, 0 = no pain, 10 = worst pain) . Motor blockade was assessed using the Bromage scoring system. The patients' satisfaction level and adverse events were also recorded. Results There were no significant differences in VAS scores, motor blockade and incidence of adverse events between the two groups. The number of effective pressing in study group was significantly less than that in control group. Starting from 4h after operation the drug consumption in study group was significantly less than that in control group. Conclusion 0.237 % ropivacaine mesylate can be used for PCEA after transabdominal hysterectomy as safely as 0.2% ropivacaine HCl.

Objective: To investigate the clinical effect of entecavir combined with pegylated interferons in the patients with hepatitis B.Methods: Totally 72 patients with hepatitis B were randomly divided into the experimental group and the control group with 36 ones in each.The patients in the experimental group were treated with entecavir combined with pegylated interferons, and those in the control group were treated with entecavir.The clinical indicators in the two groups were detected and compared after the 24-week, 48-week and 6-month treatment.The adverse drug reactions in the two groups were recorded and compared.Results: After the 24-week treatment, the differences in the clinical indicators between the groups were not statistically significant (P >0.05).After the 48-week and 6-month treatment, the clinical indicators in the experimental group were obviously higher than those in the control group, and the differences were statistically significant (P <0.05).The difference in the adverse drug reactions in the two groups was not statistically significant (P >0.05).Conclusion: Compared with entecavir, pegylated interferon combined with entecavir in the treatment of hepatitis B shows better clinical effect and security, which is more worthy of clinical promotion.

Objective To investigate the expression of serum Golgi protein 73 in hepatocellular carcinoma(HCC) and analyze the clinical significance.Methods The expression of GP73 was measured by ELISA in 75 HCC ,30 chronic hepatitis and normal con -trols.Results The serum concentrations of GP73 were (128.3 ±33.6)μg/L,(80.3 ±19.2)μg/L and (78.3 ±18.5)μg/L in the HCC, chronic hepatitis patients and normal controls .The serum level of GP73 was significantly higher in HCC than those with chronic hepatitis and healthy controls .GP73 expression was positively correlated with clinical stage , humor size and metastasis.The positive rate of GP73 in stage was 60%,higher than the AFP positive rate(33%).Conclusions The serum level of GP73 is high in HCC and was helpful for distinguishing benign and malignant liver diseases .GP73 can be used as a diagnostic marker for HCC .

In current study, the expressions of protein kinase C (PKC)-alpha, betaI and betaII as well as their correlation to the expression of transforming growth factor-betaI (TGF-betaI) and vascular endothelial growth factor (VEGF) were investigated in glomeruli of normal renal tissues taken from human kidney tumors and kidney tissues from patients with diabetic nephropathy (DN). The accumulation of glomerular extracelluar matrix (ECM) was determined by PAS staining, the expressions of PKC-a, PKC-betaI, PKC-betaII, TGF-betaI and VEGF were measured by semi-quantitative immunohistochemistry. Our results showed that in glomeruli of normal renal tissues, PKC-alpha and betaII had a strong expression whereas the expression of PKC-betaI was weak; in glomeruli of DN patients, the expressions of PKC-alpha, PKC-betaI, VEGF and TGF-betaI and the accumulation of ECM increased significantly, but the expression of PKC-betaII decreased markedly. Meanwhile, the expressions of PKC-alpha and betaI had a positive correlation to the expressions of VEGF and TGF-betaI respectively, whereas PKC-betaII showed no correlation to VEGF and TGF-betaI. It is concluded that the expressions of PKC-alpha, betaI and betaII in glomeruli of normal subjects and DN patients are different. PKC-alpha seems to play a critical role in human DN by up-regulating VEGF expression, whereas PKC-betaI is relatively important for the up-regulation of TGF-betaI and the accumulation of ECM under diabetic conditions.